Skip to main content
Erschienen in:

01.08.2006 | Leitthema

Nichtkleinzelliges Lungenkarzinom im Stadium III

Definitive Radiochemotherapie

verfasst von: Prof. Dr. M. Stuschke, R. M. Huber, M. Flentje, C. Rübe

Erschienen in: Die Onkologie | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine definitive Radiochemotherapie ist Standardtherapie für Patienten mit einem prognostisch nichtoperablen, lokal fortgeschrittenen, nichtkleinzelligen Lungenkarzinom. Zwei bis 4 Kurse einer cisplatinbasierten Chemotherapie sind in Kombination mit einer definitiven thorakalen Strahlentherapie beim prognostisch nichtoperablen nichtkleinzelligen Lungenkarzinom im Stadium IIIA/IIIB indiziert, falls keine Kontraindikation gegen die Durchführung einer Chemotherapie besteht. Die Evidenz aus randomisierten Studien weist darauf hin, dass die Chemotherapie – oder bei mehr als zwei Zyklen – eine Komponente der Chemotherapie simultan zur Strahlentherapie appliziert werden sollte. Drittgenerationkombinationen in Kombination mit einer Strahlentherapie zeigen Unterschiede in ihren Toxizitätsspektren, die für einige Kombinationen sehr günstig sind.
Literatur
1.
Zurück zum Zitat Albain KS, Swann RS, Rusch VR et al. (2005) Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for Stage IIIA(pN2) non-small cell lung cancer: Outcomes of Update of North American Intergroup Trial 0139 (RTOG9309) (Abstract #7014). J Clin Oncol 23 [Suppl]: 7014 Albain KS, Swann RS, Rusch VR et al. (2005) Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for Stage IIIA(pN2) non-small cell lung cancer: Outcomes of Update of North American Intergroup Trial 0139 (RTOG9309) (Abstract #7014). J Clin Oncol 23 [Suppl]: 7014
2.
Zurück zum Zitat Aupérin A, Le Péchoux C, Pignon JP et al.: On behalf of the Meta-Analysis of Cisplatin/carboplatin based concomitant Chemotherapy in non-small cell Lung Cancer (MA3-LC) Group (2006) Concomitant radio-chemotherapy based on platincompounds in patients with locally advanced non-small cell lung cancer: A meta-analysis of individual data from 1764 patients. Ann Oncol 17: 473–483CrossRefPubMed Aupérin A, Le Péchoux C, Pignon JP et al.: On behalf of the Meta-Analysis of Cisplatin/carboplatin based concomitant Chemotherapy in non-small cell Lung Cancer (MA3-LC) Group (2006) Concomitant radio-chemotherapy based on platincompounds in patients with locally advanced non-small cell lung cancer: A meta-analysis of individual data from 1764 patients. Ann Oncol 17: 473–483CrossRefPubMed
3.
Zurück zum Zitat Ball D et al. (1999) A phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small-cell lung cancer: final report of an Australian multicentre trial Radiother Oncol 52: 129–136 Ball D et al. (1999) A phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small-cell lung cancer: final report of an Australian multicentre trial Radiother Oncol 52: 129–136
4.
Zurück zum Zitat Bedano PM, Neubauer M, Ansari R et al. (2006) Phase III study of cisplatin plus etoposide with concurrent chest radiation followed by docetaxel vs. observation in patients with stage III non-small cell lung cancer: An interim toxicity analysis of consolidation therapy. J Clin Oncol 24 [Suppl]: 7043CrossRef Bedano PM, Neubauer M, Ansari R et al. (2006) Phase III study of cisplatin plus etoposide with concurrent chest radiation followed by docetaxel vs. observation in patients with stage III non-small cell lung cancer: An interim toxicity analysis of consolidation therapy. J Clin Oncol 24 [Suppl]: 7043CrossRef
5.
Zurück zum Zitat Belani C, Choy H, Bonomi P et al. (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 25: 5883–5891CrossRef Belani C, Choy H, Bonomi P et al. (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 25: 5883–5891CrossRef
6.
Zurück zum Zitat Belderbos JSA, De Jaeger K, Heemsbergen WD et al. (2003) First results of a phaseI/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66: 199–126CrossRef Belderbos JSA, De Jaeger K, Heemsbergen WD et al. (2003) First results of a phaseI/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66: 199–126CrossRef
7.
Zurück zum Zitat Bonner JA, Harari P, Giralt J et al. (2006) Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578CrossRefPubMed Bonner JA, Harari P, Giralt J et al. (2006) Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578CrossRefPubMed
8.
Zurück zum Zitat Bonner JA, McGinnis WL, Stella PJ et al. (1998) The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma. Cancer 82: 1037–1048CrossRefPubMed Bonner JA, McGinnis WL, Stella PJ et al. (1998) The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma. Cancer 82: 1037–1048CrossRefPubMed
9.
Zurück zum Zitat Brodin O, Nou E, Mercke C et al. (1996) Comparison of induction chemotherapy befor radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 32A: 1893–1900CrossRefPubMed Brodin O, Nou E, Mercke C et al. (1996) Comparison of induction chemotherapy befor radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 32A: 1893–1900CrossRefPubMed
10.
Zurück zum Zitat Chang DT, Zlotecki RA, Oliver KR (2005) Re-Examining the role of elective nodal irradiation. Am J Clin Oncol 28: 597–602CrossRefPubMed Chang DT, Zlotecki RA, Oliver KR (2005) Re-Examining the role of elective nodal irradiation. Am J Clin Oncol 28: 597–602CrossRefPubMed
11.
Zurück zum Zitat Clamon G et al. (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4–11PubMed Clamon G et al. (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4–11PubMed
12.
Zurück zum Zitat Curran WJ, Scott CB, Langer CJ et al. (2003) Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410 (abstr #621). J Clin Oncol 22 [Suppl 1]: 621 Curran WJ, Scott CB, Langer CJ et al. (2003) Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410 (abstr #621). J Clin Oncol 22 [Suppl 1]: 621
13.
Zurück zum Zitat De Ruysscher D, Wanders S, van Haren E et al. (2005) Selective mediastinal node irradiation based on FDG-PET scan in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62: 988–994CrossRefPubMed De Ruysscher D, Wanders S, van Haren E et al. (2005) Selective mediastinal node irradiation based on FDG-PET scan in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62: 988–994CrossRefPubMed
14.
Zurück zum Zitat Dillman RO, Herndon J, Seagren S et al. (1996) Improved survival of stage III non-small cell lung cancer: seven year follow-up of Cancer and Leukemia Group B 8433 trial. J Natl Cancer Inst 88: 1210–1215PubMed Dillman RO, Herndon J, Seagren S et al. (1996) Improved survival of stage III non-small cell lung cancer: seven year follow-up of Cancer and Leukemia Group B 8433 trial. J Natl Cancer Inst 88: 1210–1215PubMed
15.
Zurück zum Zitat Eberhardt W, Wilke H, Stamatis G et al. (1998) Preoperative chemotherapy followed by concurrent cheomradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase-II trial. J Clin Oncol 16: 622–634PubMed Eberhardt W, Wilke H, Stamatis G et al. (1998) Preoperative chemotherapy followed by concurrent cheomradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase-II trial. J Clin Oncol 16: 622–634PubMed
16.
Zurück zum Zitat Fournel P, Robinet G, Thomas P et al. (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancérologie NPC 95–01 study. J Clin Oncol 23: 5910–5917CrossRefPubMed Fournel P, Robinet G, Thomas P et al. (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancérologie NPC 95–01 study. J Clin Oncol 23: 5910–5917CrossRefPubMed
17.
Zurück zum Zitat Furuse K et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692–2699PubMed Furuse K et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692–2699PubMed
18.
Zurück zum Zitat Holloway CL, Robinson D, Murray B (2004) Results of a phse I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 73: 285–287CrossRefPubMed Holloway CL, Robinson D, Murray B (2004) Results of a phse I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 73: 285–287CrossRefPubMed
19.
Zurück zum Zitat Huber RM, Flentje M, Gosse H et al. (2004) Induction chemotherapy and following simultaneous radio/chemotehrapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB): Update of CT/RT 99/97 (abstract #7075) J Clin Oncol [Suppl 1]: 7075 Huber RM, Flentje M, Gosse H et al. (2004) Induction chemotherapy and following simultaneous radio/chemotehrapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB): Update of CT/RT 99/97 (abstract #7075) J Clin Oncol [Suppl 1]: 7075
20.
Zurück zum Zitat Jeremic B, Shibamoto Y, Acimovic L et al. (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin / etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14: 1065–1070PubMed Jeremic B, Shibamoto Y, Acimovic L et al. (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin / etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14: 1065–1070PubMed
21.
Zurück zum Zitat Jeremic B, Shibamoto YS, Acimovic L et al. (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13: 452–458PubMed Jeremic B, Shibamoto YS, Acimovic L et al. (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13: 452–458PubMed
22.
Zurück zum Zitat Kelly K, Gaspar LE, Chansky K et al. (2005) Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 23 [Suppl]: 7058 Kelly K, Gaspar LE, Chansky K et al. (2005) Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 23 [Suppl]: 7058
23.
Zurück zum Zitat Kiura K, Segawa M, Tabata N et al. (2006) Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: preliminary report. J Clin Oncol 24 [Suppl]: 7101 Kiura K, Segawa M, Tabata N et al. (2006) Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: preliminary report. J Clin Oncol 24 [Suppl]: 7101
24.
Zurück zum Zitat Le Chevalier T, Arriagada R, Quix E et al. (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417–423PubMed Le Chevalier T, Arriagada R, Quix E et al. (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417–423PubMed
25.
Zurück zum Zitat Lee CB, Socinski MA, Lin L et al. (2006) High-dose 3D chemoradiotherapy trials in stage III non-small cell lung cancer at the University of North Carolina: Long-term follow up and late complications. J Clin Oncol 24: 7145 Lee CB, Socinski MA, Lin L et al. (2006) High-dose 3D chemoradiotherapy trials in stage III non-small cell lung cancer at the University of North Carolina: Long-term follow up and late complications. J Clin Oncol 24: 7145
26.
Zurück zum Zitat McGarry RC, Papiez L, Williams M et al. (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 63: 1010–1015CrossRefPubMed McGarry RC, Papiez L, Williams M et al. (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 63: 1010–1015CrossRefPubMed
27.
Zurück zum Zitat Mok T, Zhang L, Liao M et al. (2006) Risk of severe radiation pneumonitis in gemcitabine based consolidation chemotherapy after concurrent chemo-radiation in stage III non-small-cell lung cancer. J Clin Oncol 24 [Suppl]: 17079 Mok T, Zhang L, Liao M et al. (2006) Risk of severe radiation pneumonitis in gemcitabine based consolidation chemotherapy after concurrent chemo-radiation in stage III non-small-cell lung cancer. J Clin Oncol 24 [Suppl]: 17079
28.
Zurück zum Zitat Nagata Y, Takayama K, Matsuo Y et al. (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using stereotactic body frame. Int J Radiat Oncol Biol Phys 63: 1427–1431CrossRefPubMed Nagata Y, Takayama K, Matsuo Y et al. (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using stereotactic body frame. Int J Radiat Oncol Biol Phys 63: 1427–1431CrossRefPubMed
29.
Zurück zum Zitat Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from randomised trials. B M J 311: 899–909 Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from randomised trials. B M J 311: 899–909
30.
Zurück zum Zitat Onishi H, Araki T, Shirato H et al. (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer 101: 1623–1631CrossRefPubMed Onishi H, Araki T, Shirato H et al. (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer 101: 1623–1631CrossRefPubMed
31.
Zurück zum Zitat Rosenzweig KE, Sim SE, Mychalczak B et al. (2001) Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50: 681–685CrossRefPubMed Rosenzweig KE, Sim SE, Mychalczak B et al. (2001) Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50: 681–685CrossRefPubMed
32.
Zurück zum Zitat Rowell NP, O’Rourke NP (2006) Concurrent chemoradiotherapy in non-small cell lung cancer (Review). The Cochrane Library 2006, Issue 2 Rowell NP, O’Rourke NP (2006) Concurrent chemoradiotherapy in non-small cell lung cancer (Review). The Cochrane Library 2006, Issue 2
33.
Zurück zum Zitat Saunders M, Dische S, Barrett A et al. (1999) Continuos, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52: 137–148CrossRefPubMed Saunders M, Dische S, Barrett A et al. (1999) Continuos, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52: 137–148CrossRefPubMed
34.
Zurück zum Zitat Sause WT et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, Southwest Oncology Group. Chest 117: 358–364CrossRefPubMed Sause WT et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, Southwest Oncology Group. Chest 117: 358–364CrossRefPubMed
35.
Zurück zum Zitat Scagliotti GV, Szczesna A, Ramlau R et al. (2006) Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer 94: 1375–1382CrossRefPubMed Scagliotti GV, Szczesna A, Ramlau R et al. (2006) Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer 94: 1375–1382CrossRefPubMed
36.
Zurück zum Zitat Schaake-Koning C, van den Bogaert W, Dalesio O et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524–530PubMed Schaake-Koning C, van den Bogaert W, Dalesio O et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524–530PubMed
37.
Zurück zum Zitat Senan S, De Ruysscher D, Giraud P et al.: Radiotherapy Group of European Organization for Research and Treatment of Cancer (2004) Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71: 139–146CrossRefPubMed Senan S, De Ruysscher D, Giraud P et al.: Radiotherapy Group of European Organization for Research and Treatment of Cancer (2004) Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71: 139–146CrossRefPubMed
38.
Zurück zum Zitat Van Meerbeeck J, Kramer G, Van Schil P et al. on behalf of the EORTC-Lung Cancer Group (2005) A randomized trial of radical surgery versus thoracic radiotherapy after response to induction chemotherapy in patients with histo-/cytologically proven resectable stage IIIA-N2 NSCLC (EORTC08941) (Abstract #7015). J Clin Oncol 23 [Suppl 1]: 7015CrossRef Van Meerbeeck J, Kramer G, Van Schil P et al. on behalf of the EORTC-Lung Cancer Group (2005) A randomized trial of radical surgery versus thoracic radiotherapy after response to induction chemotherapy in patients with histo-/cytologically proven resectable stage IIIA-N2 NSCLC (EORTC08941) (Abstract #7015). J Clin Oncol 23 [Suppl 1]: 7015CrossRef
39.
Zurück zum Zitat Vokes EE, Herndin II JE, Crwford J et al. (2002) Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20: 4191–4198CrossRefPubMed Vokes EE, Herndin II JE, Crwford J et al. (2002) Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20: 4191–4198CrossRefPubMed
40.
Zurück zum Zitat Zatloukal P, Petruzelka L, Zemanova M et al. (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-samll cell lung cancer: A randomized study. Lung Cancer 46: 87–98CrossRefPubMed Zatloukal P, Petruzelka L, Zemanova M et al. (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-samll cell lung cancer: A randomized study. Lung Cancer 46: 87–98CrossRefPubMed
Metadaten
Titel
Nichtkleinzelliges Lungenkarzinom im Stadium III
Definitive Radiochemotherapie
verfasst von
Prof. Dr. M. Stuschke
R. M. Huber
M. Flentje
C. Rübe
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2006
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1099-2

Weitere Artikel der Ausgabe 8/2006

Der Onkologe 8/2006 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.